Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 8 December 2009
Vol. 2, Issue 100, p. ra80
[DOI: 10.1126/scisignal.2000643]


Editor's Summary

Addicted to Only a Few
Sometimes cancer cells become dependent on a particular aberrantly activated protein, encoded by an oncogene. Thus, inhibiting the activity of such an oncogenic protein is one approach to treating cancer. Bertotti et al. found that inhibition of the oncogenic protein Met, which caused "addicted" cells to stop proliferating, only inactivated a subset of the pathways downstream of Met. They identified a signaling and transcriptional response "signature," involving Ras and phosphoinositide 3-kinase pathways, that contributed to cell-cycle arrest in response to Met inhibition in the Met-addicted cancer cells. A similar biochemical and transcriptional signature was found in response to inhibition of another oncogenic receptor tyrosine kinase, the epidermal growth factor receptor, in cells addicted to this second oncogene. Thus, cells addicted to oncogenic receptor tyrosine kinases may develop common mechanisms to sustain malignancy and therefore be susceptible to similar therapeutic interventions.

Citation: A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino, Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Sci. Signal. 2, ra80 (2009).

Read the Full Text

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab.
M. F. Burbridge, C. J. Bossard, C. Saunier, I. Fejes, A. Bruno, S. Leonce, G. Ferry, G. Da Violante, F. Bouzom, V. Cattan, et al. (2013)
Mol. Cancer Ther. 12, 1749-1762
   Abstract »    Full Text »    PDF »
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET.
C. Basilico, S. Pennacchietti, E. Vigna, C. Chiriaco, S. Arena, A. Bardelli, D. Valdembri, G. Serini, and P. Michieli (2013)
Clin. Cancer Res. 19, 2381-2392
   Abstract »    Full Text »    PDF »
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas.
G. Migliardi, F. Sassi, D. Torti, F. Galimi, E. R. Zanella, M. Buscarino, D. Ribero, A. Muratore, P. Massucco, A. Pisacane, et al. (2012)
Clin. Cancer Res. 18, 2515-2525
   Abstract »    Full Text »    PDF »
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils.
D. Torti and L. Trusolino (2011)
EMBO Mol Med. 3, 623-636
   Abstract »    Full Text »    PDF »
A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer.
A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti, C. Isella, D. Cora, F. Di Nicolantonio, M. Buscarino, C. Petti, et al. (2011)
Cancer Discovery 1, 508-523
   Abstract »    Full Text »    PDF »
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors.
V. Cepero, J. R. Sierra, S. Corso, E. Ghiso, L. Casorzo, T. Perera, P. M. Comoglio, and S. Giordano (2010)
Cancer Res. 70, 7580-7590
   Abstract »    Full Text »    PDF »
Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors.
A. Bertotti, C. Bracco, F. Girolami, D. Torti, S. Gastaldi, F. Galimi, E. Medico, P. Elvin, P. M. Comoglio, and L. Trusolino (2010)
Clin. Cancer Res. 16, 3933-3943
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882